Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Galapagos NV

www.glpg.com

Latest From Galapagos NV

Deal Watch: Roivant Spins Out Arvelle, Licenses Epilepsy Candidate From SK Biopharma

Already having launched several portfolio companies, Roivant goes a step further by spinning out CNS specialist Arvelle from Axovant. BI and IBM will incorporate blockchain technology in clinical trials, while AbbVie licenses multiple myeloma candidate from TeneoBio.

Business Strategies Commercial

Galapagos Targets Liver Fibrosis With Evotec Deal

Belgium’s Galapagos adds another potential fibrosis drug to its growing pipeline of compounds in a therapeutic area that is also attracting attention from a number of other companies.

 

Clinical Trials Deals

Lilly/Incyte’s Olumiant Breezes Ahead of JAK Pack In Atopic Dermatitis

Lilly/Incyte’s JAK inhibitor baricitinib is the first of its class to report positive Phase III data in atopic dermatitis. But will the dosing worries of Olumiant’s rheumatoid arthritis indication spoil the party?

Dermatology Research & Development

Deal Watch: Celgene Makes Alliances With Kyn, Obsidian After Bristol Buyout

Just two weeks after agreeing on a merger with Bristol, Celgene is back at its own deal-making, signing cancer-focused R&D pacts with Kyn and Obsidian. Boehringer and Bioharmony collaborate on novel therapies for hospital-acquired infections, while Sanofi teams with Biomunex on bi- and multi-specific antibodies.

Business Strategies Commercial
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Galapagos Genomics NV
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Benelux
          • Belgium
  • Parent & Subsidiaries
  • Galapagos NV
  • Senior Management
  • Onno van de Stolpe, CEO
    Bart Filius, CFO & COO
    Andre Hoekema, PhD, CBO
    Piet Wigerinck, PhD, CSO
    Walid Abi-Saab, MD, CMO
  • Contact Info
  • Galapagos NV
    Phone: (32) 15 34 29 00
    Generaal De Wittelaan L11 A3
    Mechelen, 2800
    Belgium
Advertisement
Advertisement
UsernamePublicRestriction

Register